Course Authors
Meera B. Chitlur, M.D.
Dr. Chitlur is Associate Professor, Wayne State University School of Medicine, and Director, Hemophilia Treatment Center and Hemostasis Program, Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI.
Within the past 12 months, Dr. Chitlur has been a consultant to Bayer HealthCare and Novo Nordisk.
Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose.
This activity is certified for hematologists, HEM/ONCs, surgeons, anaesthesiologists, intensivists, hospitalists, critical care medicine specialists, emergency medicine clinicians, PCPs and other healthcare providers interested in managing hospitalized patients with bleeding disorders.
This CME activity has been peer-reviewed by Henny H. Billet, M.D., Professor of Clinical Medicine, Department of Medicine (Hematology), Professor of Clinical Pathology, Department of Pathology, Chief, Division of Hematology, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY.
This activity is made possible by an unrestricted educational grant from Novo Nordisk
Estimated course time: 1 hour(s).
Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University and Educational Concepts in Medicine. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
Review the clinical presentation and laboratory diagnoses to appropriately diagnose unexplained or unusual bleeding in hospitalized patients
Employ evidence-based treatment modalities for hemostatic control of bleeding and inhibitor eradication in patients with AHA or other unexplained bleeding
Discuss treatment advances for RBDs including new and emerging recombinant products.
